Who is sponsoring NCT05421130?

NCT05421130 is sponsored by Fuji Systems Corporation.

What drugs are being tested in NCT05421130?

Interventions in NCT05421130: Selective Cerebral Perfusion Catheter.

What condition does NCT05421130 study?

NCT05421130 studies Aortic Aneurysm, Aortic Dissection, Aortic Arch Aneurysm, Aortic Arch; Aneurysm, Dissecting.

Is NCT05421130 still recruiting?

NCT05421130 is currently status unknown. Last updated 11 July 2023.

Last reviewed 2023-07-11 · How we verify

NCT05421130

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Investigation of Clinical Safety and Performance of the SP-GRIPFLOW, Selective Cerebral Perfusion Catheter When Used for Cerebral Perfusion During Aortic Arch Repair

Status unknown NA Last updated 11 July 2023

What this trial tests

NA trial testing Selective Cerebral Perfusion Catheter in Aortic Aneurysm in 149 participants. Status unknown.

Timeline

2 May 2022

Primary endpoint
1 July 2023

1 February 2024

Quick facts

Lead sponsor	Fuji Systems Corporation
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	149
Start date	2 May 2022
Primary completion	1 July 2023
Estimated completion	1 February 2024
Sites	5 locations across Netherlands, Germany

Drugs / interventions tested

Selective Cerebral Perfusion Catheter

Conditions studied

Aortic Aneurysm — all drugs for Aortic Aneurysm →
Aortic Dissection — all drugs for Aortic Dissection →
Aortic Arch Aneurysm — all drugs for Aortic Arch Aneurysm →
Aortic Arch; Aneurysm, Dissecting — all drugs for Aortic Arch; Aneurysm, Dissecting →

Sponsor

Fuji Systems Corporation

Who can join

18 and older, any sex, with Aortic Aneurysm or Aortic Dissection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if the SP-GRIPFLOW catheter (the catheter designed by Fuji Systems) is safe and how well it functions. The information from this research will be used to help decide if the device should be approved for sale in the European Union. The SP-GRIPFLOW catheter may not yet be used by investigators outside of the study. Through the study, FUJI will prove that the target flow as measured by the flow through the catheter(s)(cumulative flow for multiple catheters) was confirmed in 95% of cases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Aneurysm

Currently open trials in the same condition.

NCT07438327 — AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation · recruiting
NCT06998498 — Prehabilitation for Aortic Aneurysm Surgery: Proof-of-concept Trial · NA · recruiting
NCT06549348 — Radiation Free Study · NA · recruiting
NCT06834607 — Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Complex Aortic Aneurysms · NA · recruiting
NCT06762561 — Prophylactic Mesh Reinforcement After Open Aortic Aneurysm Repair · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05421130 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuji Systems Corporation
Last refreshed: 11 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05421130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing